Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.

Ramakrishnan,V., Bhaskar,V., Law,D.A., Wong,M.H., DuBridge,R.B., Breinberg,D., O'Hara,C., Powers,D.B., Liu,G., Grove,J., Hevezi,P., Cass,K.M., Watson,S., Evangelista,F., Powers,R.A., Finck,B., Wills,M., Caras,I., Fang,Y., McDonald,D., Johnson,D., Murray,R., and Jeffry,U. 2006. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J. Exp. Ther. Oncol. 5, 273-286.